Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small cell lung cancer (NSCLC) with crizotinib has led to dramatic responses. While crizotinib is approved for use in EML4-ALK positive NSCLC for targeted inhibition of ALK, the drug also inhibits MET, MST1R (RON), ROS1, and more recently, has been reported to inhibit the ALK homolog LTK. To further understand the expanded therapeutic potential of crizotinib, a genomic survey to identify aberrations in ALK, MET, MST1R (RON), ROS1 and LTK was performed across >90,000 samples in the Oncomine Knowledgebase, including >7,000 samples subjected to full exome sequencing to identify known and novel fusion events. In this session, Dr. Eddy will reveal novel findings identified in this analysis including recurrent ALK fusions in colorectal adenocarcinoma, papillary renal cell carcinoma, thyroid gland carcinoma and sarcoma, as well as confirmation of the EML4-ALK fusion in lung adenocarcinoma. In this session, Dr. Eddy will highlight key findings of the analysis and provide an overall breakdown of molecular aberrations by cancer type.